Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This study will examine the use of Aflibercept in patients with exudative macular
degeneration requiring intravitreal injections. Patients will be followed for 24 months. The
follow up phase will be completed at month 36.